The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

A groundbreaking study by researchers at the Queensland Brain Institute reveals that low-intensity ultrasound therapy can ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Alzheimer’s disease is usually associated with old age. But around 5%-10% of all Alzheimer’s cases occur in people under the age of 65. Early-onset Alzheimer’s disease progresses more rapidly and ...

A new study conducted by researchers from the Washington University School of Medicine identified an experimental drug that ...

McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...

Certain widely used drug combinations may either slow down or worsen the progression of Alzheimer's disease, but their ...

An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease.